IMDX — Insight Molecular Diagnostics Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1642380 ·
Last close
$1.66
Market Cap
$54.32M
52W High
$7.51
52W Low
$1.50
ADV30
237,357
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 239,000 | 157,000 | -9,088,000 | -11,260,000 | 29,443,000 | 17,756,000 | 50,742,000 |
| Mar 2026 | 32,000 | 15,000 | -10,331,000 | -4,290,000 | 40,427,000 | 28,201,000 | 51,118,000 |
| Dec 2025 | 1,139,000 | 496,000 | -9,950,000 | -22,955,000 | 25,756,000 | 11,583,000 | 57,220,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-27,078,000
Investing CF
$-3,921,000
Financing CF
$23,762,000
CapEx
$-3,921,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.49
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-416,311,000
Inventory
$207,000
Receivables
$192,000
ST Investments
—
EBIT TTM
$-49,261,000
Pretax Income TTM
$-49,359,000
Interest Exp TTM
$98,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,670,000
EBITDA
$-34,543,000
Free Cash Flow
$-18,789,500
Enterprise Value
$122,310,992
Total Cash
$17,756,000
Total Debt
$2,625,000
Shares Out
32,724,284
Trailing EPS
$-1.52
Book Value
$-0.65
ROE
—
ROA
-57.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,055,000 | -30,578,000 | -50,222,000 | 25,756,000 | 57,220,000 | -31,464,000 | -22,184,000 |
| Dec 2024 | 1,881,000 | -23,247,000 | -60,663,000 | 35,081,000 | 47,355,000 | -12,274,000 | -20,689,000 |
| Dec 2023 | 1,503,000 | -22,417,000 | -27,781,000 | 74,892,000 | 54,424,000 | 20,468,000 | -23,325,000 |
| Dec 2022 | 958,000 | -28,852,000 | -72,902,000 | 100,091,000 | 65,799,000 | 34,292,000 | -45,568,000 |
TTM Snapshot
Revenues TTM
$1,670,000
NetIncome TTM
$-49,359,000
OpCashFlow TTM
—
Assets (Latest)
$29,443,000
Forward EPS
$-0.80
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $1.66 · call volume: 14 · put volume: 5
Expected Move to 2026-12-18:
±$3.40
(204.82%) —
implied range
$-1.74 –
$5.06
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IBAC | IB Acquisition Corp. | $54.33M | $10.85 | — |
| ICCC | IMMUCELL CORP /DE/ | $101.55M | $11.17 | — |
| MXCT | MAXCYTE, INC. | $132.16M | $1.28 | — |
| NNNN | Anbio Biotechnology | $160.20M | $3.65 | — |
| ONMD | OneMedNet Corp | $267.38M | $4.51 | — |
News headlines (Yahoo Finance, 1h cache)
Insight Molecular Diagnostics (IMDX) Stock Sees Fair Value Cut As FDA Questions Cloud Analyst Views
2026-11-20 01:13 · Yahoo
Insight Molecular (IMDX) Q3 2026 Earnings Call Transcript
2026-11-17 16:28 · Yahoo
Insight Molecular Diagnostics Inc. Q3 2026 Earnings Call Summary
2026-11-17 13:30 · Yahoo
Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering
2026-11-17 13:00 · Yahoo
Insight Molecular Diagnostics: Q3 Earnings Snapshot
2026-11-16 22:47 · Yahoo
Insight Molecular Diagnostics stock tumbles on public offering
2026-11-16 22:43 · Yahoo
IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
2026-11-16 21:56 · Yahoo
Insight Molecular Diagnostics Announces Proposed Public Offering
2026-11-16 21:10 · Yahoo
iMDx to Release Third Quarter Results on November 16, 2026
2026-11-05 12:00 · Yahoo
iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
2026-10-14 12:00 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-19 17:58:07 | 2026-11-17 | Broadwood Partners, L.P. | 10% | P - Purchase | 1.75 | 3428571 | 5999999 |